aid: korro-bio
name: Korro Bio
description: >-
  Korro Bio, Inc. (Nasdaq: KRRO) is a Cambridge, Massachusetts clinical-stage biopharmaceutical
  company developing a new class of genetic medicines based on programmable RNA editing. Its
  proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform pairs data-driven
  oligonucleotide design and machine-learning optimization with linker chemistry and
  tissue-directed delivery to recruit the body's own ADAR enzymes and make a precise, transient
  single-base edit to a native mRNA transcript — editing RNA rather than DNA so the change is
  tunable and reversible. The company was created and incubated by Atlas Venture with New
  Enterprise Associates in October 2019, raised a $91.5M Series A and a $116M Series B, and became
  public in 2023 through a merger with Frequency Therapeutics alongside a $117M private placement.
  Its pipeline targets liver and central nervous system indications and includes KRRO-110 (the
  REWRITE Phase 1/2a study in alpha-1 antitrypsin deficiency), KRRO-111 and KRRO-121, which holds
  EMA orphan drug designation for urea cycle disorders. Korro Bio sells therapeutics, not software:
  it operates no developer program, publishes no API, SDK or machine-readable specification, and
  maintains no public source-code organization.
url: https://raw.githubusercontent.com/api-evangelist/korro-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline
specificationVersion: '0.23'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- RNA Editing
- Genetic Medicine
- Drug Discovery
- Life Sciences
- Clinical Trials
- Rare Disease
- Research
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/korro-bio-domain-security.yml
- type: Website
  url: https://korrobio.com/
- type: InvestorRelations
  url: https://ir.korrobio.com/
- type: Careers
  url: https://korrobio.com/careers/
- type: TermsOfService
  url: https://korrobio.com/terms-conditions/
- type: PrivacyPolicy
  url: https://korrobio.com/privacy-policy/
- type: SecondaryMarket
  url: https://forgeglobal.com/korro-bio_stock/
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Korro Bio is a clinical-stage RNA-editing biopharmaceutical company (Nasdaq: KRRO) whose
    product is a drug pipeline, not software — there is no developer program, no API, no SDK on
    npm or PyPI and no GitHub organization; korrobio.com is a WordPress marketing site that
    answers every path, including the root, with a SiteGround robot-challenge (HTTP 202), and
    api./dev./docs./developer./mcp. are wildcard DNS to the same address rather than real hosts.
  evidence:
  - url: https://korrobio.com/
    status: 202
  - url: https://korrobio.com/openapi.json
    status: 202
  - url: https://ir.korrobio.com/.well-known/security.txt
    status: 404
  - url: https://ir.korrobio.com/llms.txt
    status: 404
  - url: https://ir.korrobio.com/
    status: 200
  - url: https://api.github.com/search/users?q=korro+bio
    status: 200
  checked: '2026-08-23'